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Abstract
Background—Oxaliplatin was rapidly adopted for treatment of stage III colon cancer after FDA 
approval in November 2004, thus providing an opportunity to use calendar time as an instrumental 
variable (IV) in nonexperimental comparative effectiveness research. Assuming instrument 
validity, IV analyses account for unmeasured confounding and are particularly valuable in sub-
populations of unresolved effectiveness such as older individuals.
Methods—We examined stage III colon cancer patients aged 65+ initiating chemotherapy 
between 2003–2008 using U.S. population-based cancer registry data linked with Medicare claims 
(N=3660). Risk differences (RD) for all-cause mortality were derived from Kaplan-Meier survival 
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curves. We examined Instrumental Variable strength and compared RDs with propensity score 
estimates.
Results—Calendar time greatly affected oxaliplatin receipt. The calendar time instrument 
compared patients treated from January 2003 through September 2004 (N=1449) with those 
treated from March 2005 through May 2007 (N=1432), resulting in 54% compliance. The 1-,2-,3-
year local average treatment effect of the risk differences per 100 patients in the “compliers” (95% 
confidence intervals) were −4.6(−8.2,−0.4), −6.3(−11.9,−0.2), and −9.2(−14.7,−2.5), respectively. 
Corresponding propensity score-matched results were −1.9(−4.0,0.2), −3.4(−6.2,−0.1), and 
−4.3(−7.5,−1.0).
Conclusions—IV and propensity score analyses both indicate better survival among patients 
treated with oxaliplatin. As these results are based on different populations and assumptions, the 
IV analysis adds to evidence of oxaliplatin's effectiveness in older adults, who bear the greatest 
burden of colon cancer yet were underrepresented in clinical trials. In nonexperimental 
comparative effectiveness research of rapidly emerging therapies, the potential to use calendar 
time as an IV is worth consideration.
Colon cancer is the third most common cancer with nearly 100,000 incident cases per year 
in the U.S., and the third most deadly with over 50,000 deaths per year.1 Based on superior 
efficacy demonstrated in the 2003 MOSAIC trial2,3 and subsequent FDA approval in 2004, 
the drug oxaliplatin was rapidly adopted as treatment for stage III colon cancer as part of a 
multi-agent chemotherapy. This innovation was broadly adopted and has become the 
standard of care despite gaps in knowledge regarding drug benefits for specific 
subpopulations, including older patients. Indeed, the MOSAIC trial did not include patients 
over the age of 75 and had a median patient age of 60,2 much younger than the median age 
of colon cancer diagnosis, 72.1 Subsequent studies have produced inconclusive or 
contradictory results among diverse sub-populations and this drug’s effectiveness in the 
older population remains unknown, prompting a need for additional research and robust 
methodologies.4,5,6,7
Nonexperimental comparative effectiveness research can address gaps and unanswered 
questions that commonly accompany new treatments. Comparative effectiveness research 
often relies on secondary data such as administrative or linked databases that have many 
strengths, including large, diverse study populations and long periods of follow-up.8 A 
common weakness of these data is that key confounders such as functional status, frailty and 
disease severity are often missing or are recorded with differential fastidiousness between 
providers.9 These factors can bias analyses that assume no unmeasured confounding, 
including those relying on propensity score adjustment.10,11
When a suitable instrument exists, instrumental variable (IV) methods can address these 
challenges. An IV is an observed variable that predicts treatment based on the context 
surrounding treatment receipt, which effectively pseudo-randomizes the population. This 
replaces the assumption of no unmeasured confounding with assumptions around the 
instrument’s association with treatment and its relationship with confounders and the 
outcome.
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The case of rapid innovation diffusion and oxaliplatin effectiveness among older cancer 
patients provides an excellent platform for employing IV methods. New treatments often 
experience rapid dissemination upon arrival to the market, and treatment decisions may be 
driven by external factors rather than patient-centric characteristics. In this context, calendar 
time proximal to FDA approval or other drug lifecycle events may serve as a good 
instrument for treatment receipt.
Objective
The objective of this study is to demonstrate the utility of calendar time as an effective 
instrumental variable, and in doing so examine the effectiveness of an innovative cancer 
treatment, oxaliplatin, in the older colon cancer population at the time of the drug’s initial 
adoption. We focused on the period before and during oxaliplatin’s dissemination, with 
attention on FDA approval for stage III colon cancer as a pivotal timepoint. We compared 
instrumental variable estimates for the effect in the compliers with a diverse set of 




Patients were drawn from Surveillance, Epidemiology and End Results (SEER)-Medicare 
linked data.14,15 The cohort included individuals aged 65 and older from 12 US states who 
were diagnosed with primary stage III colon cancer between 2003 and 2007, with follow-up 
through April 2010. To be eligible, patients had to receive surgical resection within 90 days 
of diagnosis, survive longer than 30 days, and initiate either oxaliplatin or 5-FU/capecitabine 
without oxaliplatin within 110 days of surgery and 120 days of diagnosis (SEER does not 
collect diagnosis day; rationale described elsewhere14,16). Patients were excluded if they 
received radiation, were diagnosed at autopsy, or had HMO coverage or incomplete 
Medicare claims during the 12 months pre- and post-diagnosis (or until death).
Instrumental variable
IV methods replace the assumption of no unmeasured confounding with the following 
conditions: the instrument 1) is associated with treatment receipt, 2) is related to the 
outcome only through treatment (exclusion restriction), and 3) does not share any causes 
with the outcome (independence restriction). An additional assumption of monotonicity 
allows us to estimate the average treatment effect in the “compliers”.12,13
To specify the IV, we defined a binary measure of calendar time based on the month and 
year of first treatment receipt anchored around oxaliplatin’s FDA approval for stage III colon 
cancer and subsequent rapid adoption. In our study, monotonicity holds if there are no 
patients who would have received oxaliplatin if diagnosed with cancer and treated before the 
date of FDA approval, yet would not have received it if treated after approval (“defier”). 
Analogously, “compliers” are patients whose initial treatment is determined by the calendar 
time in which their treatment was received: 5-FU if diagnosed and treated before FDA 
approval and oxaliplatin if treated after approval.
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We identified the “optimal” IV measure through evaluation of two criteria: 1) the 
compliance percentage (i.e., strength of the instrument’s effect on treatment receipt)17 and 2) 
the shortest overall time-span, to reduce the potential for violating IV assumptions. To 
achieve the latter, we excluded patients treated several years after FDA approval by 
truncating cohort enrollment while using all follow-up time. This minimized the effects of 
calendar time on survival, directly or indirectly, through changes in diagnostic paradigms or 
improvements in care unrelated to chemotherapy (assumption 2). Additionally, we tested the 
effect of excluding those treated in the months immediately surrounding FDA approval, 
when information dissemination and drug access may have been ambiguous. We examined 
the instrument in relation to IV assumptions using measured covariates, falsification tests, 
expert knowledge, and time trends.13,18 These time trends were examined relative to the 
inception of oxaliplatin-based treatment options as well as other possible changes in colon 
cancer care that may have created an association between time and mortality. Calendar-time 
intervals for the instrument were decided prior to examination of effect estimates.
Exposure and outcome
First treatment receipt was defined as the date of first 5-FU/capecitabine claim with no 
oxaliplatin claim within 30 days (unexposed) or the date of first oxaliplatin claim with or 
without the presence of 5-FU/capecitabine (exposed). We ignored oxaliplatin claims that 
occurred greater than 30 days after 5-FU/capecitabine receipt, because we are only 
interested in the first treatment received. However, because late receipt of oxaliplatin may 
suggest that these individuals had a recurrence or were too sick to initially receive 
oxaliplatin, a sensitivity analysis excluding these patients (n=46) was performed. All-cause 
mortality information was based on date of death according to Medicare via the U.S. Social 
Security Administration.19
Analysis
We derived risk of mortality from Kaplan-Meier survival curves and estimated 1-,2-, and 3-
year mortality risk differences (RD). Instrumental variable RDs were scaled by the 
compliance percentage to estimate the average treatment effect among “compliers” (main 
analysis).17 The Balke-Pearl method20 was used to place bounds around the instrumental 
variable point estimate for the average treatment effect in the population. We generated 
covariate-adjusted IV estimates of the RDs using inverse-probability of treatment-weighted 
(IPTW) Kaplan-Meier methods to estimate the effect of the IV on the outcome and then 
scaled this by the strength of the instrument. For comparison, we generated propensity score 
estimates using both matching and IPTW to account for all measured confounders.21,22 
These methods are based on different assumptions and resulted in appreciably different 
patient populations.
Previous literature guided identification of potential confounders: age, sex, race, tumor 
grade, tumor substage at diagnosis (IIIA-IIIC), urban/rural status, socioeconomic status, 
physician organizational affiliation with a National Cancer Institute (NCI) Cooperative 
Group,23,24 and 13 prevalent comorbidities from the Charlson comorbidity index.25 Follow-
up began on the date of first treatment receipt for 5-FU and 1 day after for oxaliplatin (based 
on observed median oxaliplatin start time after 5-FU to avoid systematic differences between 
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exposure groups). Propensity score models used the full study population and sensitivity 
analyses were performed in the reduced IV cohort to evaluate selection differences that may 
have been induced based on IV exclusions. All analyses were conducted using SAS version 
9.2. (SAS Institute, Cary, NC). The UNC Office of Human Research Ethics (IRB study 
number 12–0139) approved this study.
RESULTS
Calendar time greatly affected treatment receipt (Figure 1). The “optimal” 2-level calendar 
time instrument compared patients treated from January 2003 through September 2004 
(n=1449) with those treated from March 2005 through May 2007 (n=1432). This excluded 
patients treated during two separate time periods in the oxaliplatin lifecycle: 1) an interim 
period, when oxaliplatin use first exceeded 40% until it was used in the majority of patients, 
indicating a change in the standard of care and 2) 2.5 years after FDA approval, when the 
market for innovation was likely functionally saturated and calendar time unlikely to further 
dictate treatment choice. This IV definition produced oxaliplatin treatment rates of 11% and 
65% in the early vs. late arms of the instrument and thus yielded 54% compliance.
Measured patient characteristics were well balanced between instrument levels (Table 1), 
thereby supporting the assumption that the IV is unrelated to patient risk factors for the 
outcome. Prevalence differences for covariates stratified by the IV compared with treatment 
assignment were greatly attenuated, which further indicates a strong instrument that may be 
independent of unmeasured covariates (assumptions 1,3).17 The IV particularly improved 
balance for age, substage and cooperative group. For example the difference in the 
percentage of 65–69 year old patients was 13.6 between treatment groups but only 3.7 across 
the IV.
In the reduced IV population, we observed 11.7 deaths per person-year in the 5-FU group 
and 8.7 in the oxaliplatin group (Table 2). The 1-,2-, and 3-year mortality risks were 11.3, 
21.6, and 29.4% in the 5-FU treatment group and 7.9, 16.9 and 23.0% in the oxaliplatin 
group. The IV estimate of the 3-year RD per 100 patients for all-cause mortality was −9.2 
(−14.7, −2.5), which suggests that for every 100 compliant patients treated with oxaliplatin, 
9 additional patients survived to 3 years compared with those treated with 5-FU or 
capecitabine alone. One- and two-year IV RDs per 100 patients were −4.6 (−8.2,−0.4) and 
−6.3 (−11.9,−0.2), with bounds of (−16,30), (−20,26), and (−23,24) for 1–3 year RDs, 
respectively. Covariate-adjusted IV estimates were virtually identical (Table 3 and Figure 2).
IV results were consistent with propensity score comparators, although slightly less precise 
and further from the null; all suggested a protective effect (Figures 3, 4). Propensity score 
results agreed regardless of adjustment method.
Sensitivity analyses
We conducted 4 sensitivity analyses as follows: 1) Two additional sets of propensity score-
matched26 estimates which included calendar time alone and as an interaction term with 
each measured covariate21, 2) propensity score-matched and weighted analyses in reduced 
IV population rather than full study population, 3) instrument defined by a cutpoint rather 
Mack et al. Page 5













than interim exclusion, and 4) removed 46 patients initiating oxaliplatin more than after 30 
days of chemotherapy inception. None of these results substantially differed from our main 
findings; absolute changes in risk differences per 100 patients were ≤2.2 (eAppendix A).
DISCUSSION
In this study, we used methods within nonexperimental data to study comparative 
effectiveness of oxaliplatin-based therapy vs. the prior standard of care for older stage III 
colon cancer patients. The IV analyses controls, at least in part, for unmeasured 
confounding, which is especially problematic for studies of older patients who are 
disproportionately affected by the disease yet poorly represented in RCTs. Across diverse 
analytic approaches, we consistently found that oxaliplatin reduces all-cause mortality 
compared with 5-FU alone in this population. Results were generally consistent with effects 
observed in the younger population of the MOSAIC RCT, which reported 2 and 3-year RD 
per 100 patients of −2 (−5,2) and −3 (−7,1) (derived from Kaplan-Meier survival curves) (A. 
de Gramont, written communication, December 2012). The stability of these effectiveness 
estimates within different populations and in the presence of differing assumptions provides 
important information about oxaliplatin effectiveness in older adults, which could aid in 
decision-making among patients, providers, and policy-makers.
Results across the various methods generalize to different populations and therefore apply to 
potentially dissimilar subgroups.12 The IV estimates the average treatment effect in 54% of 
the IV cohort (the “compliers”). The IPTW-adjusted propensity score also estimates the 
average treatment effect, which applies to all patients indicated for treatment. Propensity 
score matching estimates the treatment effect in the oxaliplatin-treated patients who were 
successfully matched to 5-FU patients. An examination of patient characteristic distributions 
between the key populations22 showed general similarity, although the compliers were 
slightly younger than the overall population and more likely to have tumors identified as 
substage B, over C (eAppendix B). These differences make clinical sense, as older age and 
the accompanying reduced functional status are major reasons that a patient would receive 5-
FU in the time period when oxaliplatin would be predicted by the instrument (i.e. non-
compliance). That oxaliplatin-treated patients would be more likely to have a more 
aggressive substage (substage C) is also consistent with clinical practice.
While estimates generally agreed, the magnitude of oxaliplatin effectiveness in this older 
population cannot be confirmed due to the inability to empirically test assumptions required 
by these analyses. Validity of propensity score estimates could be compromised because of 
unmeasured confounding, which could occur through lack of data on patient frailty, and 
disease severity not captured by staging. Although this would be less pronounced due to 
comparison with an active treatment, the increased toxicity and cost associated with 
oxaliplatin may contribute to unmeasured confounding, particularly in this older population. 
If time is an instrument rather than a confounder, propensity score comparators that adjust 
for calendar year may be more biased in the presence of unmeasured confounding.27,28
IV assumptions could also be violated. While we were able to verify that calendar time’s 
relation to oxaliplatin receipt was strong during the study years, time could affect mortality 
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in ways other than through treatment and, as in all IV analyses, the exclusion restriction is 
not empirically verifiable. We mitigated this possibility by carefully considering the means 
through which calendar time might affect mortality other than through treatment changes 
and truncated the cohort accordingly. Stage migration or improvements in surgical 
techniques and other non-chemotherapeutic treatments could also create an association 
between time and mortality. However, AJCC tumor staging guidelines29 and oncologist 
interviews suggested that this was unlikely between January 2003 and May 2007. Five-year 
relative survival in colon cancer patients improved from 1975 to 2004 according to more 
inclusive national statistics;30 this trend flattens after 2000, however, and is not strong 
enough to explain our observed results over a narrow time interval. The percentage of stage 
III patients who received no chemotherapy did not change from 2003 to 2007 for most 
patients, although those over 80 became slightly less likely to receive adjuvant 
chemotherapy in later study years. It is possible that in the oldest age groups, sicker patients 
who may have been included in the study in early years may not have qualified in later 
years, thereby indirectly associating calendar time with decreased mortality. The improved 
balance of measured confounders by IV level shown in table 1 supports that the 
independence restriction, also not verifiable, may be upheld. The following falsification tests 
did not find violations of the IV conditions: 13,31 1) Comparison of IV results with 
conventional estimates (Table 3) and 2) comparison of IV strength and subgroup estimates 
for potentially modifying factors, as identified in prior investigations21 (eAppendix C).
The width of the bounds for the IV suggests that our estimate relies heavily on the 
assumption of monotonicity; we did not compute equivalent bounds for unmeasured 
confounding for the propensity score estimates. Monotonicity is clinically reasonable in this 
setting, as it is improbable that a patient would receive oxaliplatin off-label prior to FDA 
approval, yet (holding all other considerations constant) that an identical patient would 
receive 5-FU alone after FDA approval. Adverse event reports that would preclude an early 
oxaliplatin patient from receiving oxaliplatin in a later calendar month were unlikely to be 
an issue over this time period. While it is possible that physician-observed neuropathy may 
eventually have deterred an oncologist from prescribing oxaliplatin to a diabetic patient in 
later years, it is very unlikely that such patients would be preferentially treated with 
oxaliplatin in 2003 and 2004.33
The overall consistency of results between these methods suggests oxaliplatin is effective 
among older adults, a finding which is robust to the absence of measured or unmeasured 
confounding. While chance is a plausible explanation for the slight differences between the 
IV and propensity score point estimates, the divergence in direction from the unadjusted 
estimate may provide insight into differing abilities to control for measured versus 
unmeasured confounding. IV effect estimates may reflect control of unmeasured 
confounders that increase both mortality and probability of receiving oxaliplatin. For 
example, tumor pathology information regarding extent and aggressiveness of the cancer is 
not entirely captured by the relatively coarse grade and substage variables. This unmeasured 
disease severity information would be accounted for in slightly stronger IV estimates, while 
biasing propensity score estimates toward the null (in this example). Removal of tumor 
substage and grade from the propensity score model moved the results closer to the null, 
thereby supporting this theory. Treatment effect heterogeneity is another possibility, as 
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oxaliplatin may be more effective in the medium-health “compliers” than the healthier 
always-treated or not contraindicated patients, who may have survived up to 3 years 
regardless of treatment.
Some limitations of claims data, in general and specific to SEER-Medicare, apply to this 
study.14 Medicare has an estimated 75% sensitivity for 5-FU,34 and therefore a proportion of 
the referent group may have been missed. Comorbidity assessed through claims may be 
underestimated in this population, as older age is associated with less aggressive treatment 
and coding for a number of diseases.35 We used Kaplan-Meier survival curves to allow us to 
use all available patients and to avoid conditioning on follow-up; however, exclusion of a 
small number of patients with incomplete claims or HMO coverage after diagnosis could 
introduce selection bias. This exclusion was necessary in order to obtain treatment data. The 
group of patients that were excluded from this analysis due to lack of chemotherapy receipt 
may have included patients that died before their planned treatment was initiated. If 
treatment delays were more common in earlier years, this could have biased our IV 
estimates; however, the overall number of patients who would be eligible to fall into this 
category (a subset of n=293) is small. We did not use calendar time as a continuous 
instrumental variable, as there is not a practical interpretation of compliers in this setting. 
Finally, we cannot exclude chance as an alternative explanation for our findings.
In the presence of emerging therapies, consideration should be given to treatment variability 
by calendar time and the contribution of dissemination patterns to treatment recepit.21 When 
clinical uptake of treatment occurs quickly over a narrow time interval, calendar time is a 
plausible instrument that can account for bias due to unmeasured confounding. In this case, 
clinical paradigms outside of the new treatment should be closely investigated to ensure 
stability during the study time period. Over longer timeframes, calendar time may be a 
confounder, and is often treated as such by default.36 The utility of calendar time as an IV 
has been shown by Cain,37 Johnston,38 and Shetty39 et al when, similar to this setting, trends 
in medication use create a natural experiment that can be used to strengthen clinical 
evidence. In studies where sample size is small, the inefficiencies of IV methods may result 
in confidence intervals that are uninformative; however, in pharmacoepidemiology studies 
using large databases, the primary concern is often bias rather than imprecision.
Nonexperimental research is necessary to answer questions of treatment effectiveness but 
requires careful attention to methods and examination of potential biases. This study 
exemplifies this while answering a high priority clinical question on the comparative 
effectiveness of oxaliplatin vs. 5-FU in older patients, who are the most affected by colon 
cancer yet were underrepresented in clinical trials. The methods presented address different 
biases and assumptions which cannot be directly quantified, such as the effect of 
unmeasured confounding or the exact relationship of a natural instrument with exposures 
and outcomes. The presentation of a consistent set of results based on different methods and 
assumptions builds needed confidence regarding the benefit of oxaliplatin in older adults in a 
real-world population.
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Dissemination of Oxaliplatin: Receipt of Oxaliplatin vs. 5-fluorouracil for Stage III Colon 
Cancer By Month and Definition of Calendar Time Instrumental Variable (N=3660)
Points indicate the percentage of patients in each month receiving oxaliplatin or 5-FU. Grey 
shading indicates excluded patients due to interim period (October 2004-February 2005) and 
the truncation period of June 2007 and later. For illustrative purposes, diffusion patterns for 
each treatment are fitted with fourth-order polynomial trendline. The intersection point of 
lines is not statistically meaningful in terms of dissemination activity. Due to SEER-
Medicare confidentiality requirements, treatment years 2003 and 2004 are combined.
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Covariate-adjusted Instrumental Variable estimate of the Risk Difference and 95% 
Confidence Interval by day over 3-year follow-up
To compute a covariate-adjusted instrumental variable estimator of a risk difference, we first 
estimated the numerator of Wald statistic using inverse-probability of treatment-weighted 
Kaplan-Meier estimates of the cumulative incidence of mortality within each level of the 
instrumental variable. Here probability of 'treatment' is actually the probability that the 
instrumental variable takes the value 1, denoting the period after the FDA label change. This 
approach provides an estimate of the effect of the instrument on the risk of mortality (at 
various time points), adjusted for covariates. The inverse-probability weights were derived 
from propensity scores that were estimated using additive logistic models. Age and income 
were entered into the model using thin plate regression splines. The denominator of the 
Wald statistic was estimated using a linear probability model for treatment that included all 
covariates, in addition to the instrumental variable. We computed confidence intervals using 
a non-parametric bootstrap in which both the models for the numerator and denominator of 
the Wald statistic were re-estimated within each of 250 bootstrap re-samples.
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Probability of Overall Survival A) by Calendar Time Instrumental Variable (N=2881) and B) 
With 5-FU vs. Oxaliplatin in Matched Propensity Score Analysis (N=2732)
A) Patient assignment to instrumental variable category is based on month treatment was 
first received. January 2003-September 2004 (pre-FDA approval, referent) is compared with 
March 2004-May 2007 (post-FDA approval).
B) Propensity score-matched analysis adjusts for age, sex, race, tumor grade, tumor substage 
at diagnosis (IIIA-IIIC), urban/rural status, socioeconomic status measured using number of 
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months of state buy-in and census percentage of high school graduates, physician 
organizational affiliation with a National Cancer Institute (NCI) Cooperative Group, and 
comorbidities.
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Comparison of Risk Differences Estimating Comparative Effectiveness of Oxaliplatin vs. 5-
fluorouracil
Estimates of RD are based on risks per 100 patients taken from Kaplan-Meier survival 
curves. The instrumental variable estimator is scaled by a compliance percentage of 54%. 
Adjusted estimates account for the variables presented in Table 1 except year.
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